Israel Biotech Fund

The firm invests across the life-science development continuum, from preclinical seed rounds through to late-stage clinical assets and occasional crossover or PIPE transactions. By maintaining this flexible stage mandate, the fund can follow portfolio companies from academic spin-out through to regulatory approval and commercialization.

The fund's deal pipeline is built on deep ties to Israeli academic tech-transfer offices, particularly those of the Weizmann Institute of Science and Hebrew University. Founding and senior team members with backgrounds at Teva and Israeli research institutions create a proprietary sourcing channel that surfaces therapeutic programs before they reach international syndicates.

The portfolio concentrates on precision oncology, immunology, and neurodegenerative diseases. Within these verticals, the fund backs both biologic and small-molecule drug-discovery platforms, as well as enabling technologies such as AI-driven target identification and novel drug-delivery systems.

Israel Biotech Fund is structured as an asset manager operating private equity and venture capital strategies, not a single family office. The fund pools external institutional capital alongside its own commitments to invest in Israeli biotechnology companies.

The fund frequently co-invests alongside or structures co-development agreements with global pharmaceutical partners. These relationships provide portfolio companies with validation, clinical development infrastructure, and eventual exit pathways, while giving pharma partners early access to Israeli-originated therapeutic innovation.